Cargando…
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
The median overall survival for children with diffuse intrinsic pontine glioma (DIPG) is less than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs, harbor an amino acid substitution from lysine (K) to methionine (M) at position 27 of histone 3 variant 3 (H3.3). Fr...
Autores principales: | Chheda, Zinal S., Kohanbash, Gary, Okada, Kaori, Jahan, Naznin, Sidney, John, Pecoraro, Matteo, Yang, Xinbo, Carrera, Diego A., Downey, Kira M., Shrivastav, Shruti, Liu, Shuming, Lin, Yi, Lagisetti, Chetana, Chuntova, Pavlina, Watchmaker, Payal B., Mueller, Sabine, Pollack, Ian F., Rajalingam, Raja, Carcaboso, Angel M., Mann, Matthias, Sette, Alessandro, Garcia, K. Christopher, Hou, Yafei, Okada, Hideho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748856/ https://www.ncbi.nlm.nih.gov/pubmed/29203539 http://dx.doi.org/10.1084/jem.20171046 |
Ejemplares similares
-
Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
por: Hou, Yafei, et al.
Publicado: (2015) -
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
por: Chheda, Zinal S, et al.
Publicado: (2023) -
IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020) -
Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019) -
IDH mutation-induced suppression of type-1 anti-glioma immune response
por: Kohanbash, Gary, et al.
Publicado: (2015)